In the News

As a new and emerging company Movetis is regularly in the media spotlight. You can find below a selection of the latest news articles - older articles are kept in the news archive.

• PERSBERICHT: Het op één na meest gevorderde product van Movetis gaat door naar Fase IIb studie na positieve resultaten voor cirrosegerelateerde ascites
• PRESS RELEASE: Movetis’ second most advanced product progresses to Phase IIb trial following positive results in cirrhotic ascites
• Abstract - Efficacy of 12-week treatment with prucalopride (Resolor®) in patients with chronic constipation: combined results of three identical randomized, double-blind, placebo-controlled phase III trials
• Abstract - Safety and tolerability of prucalopride (Resolor®) in patients with chronic constipation: pooled data from three pivotal phase III studies
• Abstract - Long-term follow-up study of oral prucalopride (Resolor®) administered to patients with chronic constipation
• Abstract - Evaluation of the efficacy, safety and tolerability of prucalopride (Resolor®) given subcutaneously in patients undergoing elective partial colectomies
• Abstract - Cardiovascular safety of prucalopride (Resolor®) in healthy subjects: results from a randomized, double-blind, placebo-controlled, cross-over trial
• Abstract - Randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor®) in patients with opioid-induced constipation
• Abstract - Randomized double-blind placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor®) in elderly patients with chronic constipation
• Press Release - New published data support safety and efficacy of RESOLOR® for treatment of chronic constipation
• Press Release - Movetis files RESOLOR® with EMEA for the indication of chronic constipation
• Movetis presents new data at Digestive Disease Week
• Opportunities in Gastroenterology
• 'Een kleinere structuur kan zich meer focussen en sneller beslissen'
• Nog wel toekomst in maag en darm
• Movetis brengt meer innovatie in gastro-enterologie
• Movetis ouvre la vole à plus d'innovation en gastro-enterologie
• Spin-off van Janssen Pharmaceutica Movetis nadert productlancering
• Une nouvelle classe d’agonistes très sélectifs des récepteurs 5-HT4 ouvre des perspectives à une nouvelle génération de médicaments pour les maladies gastro-intestinales (GI)
• Nieuwe klasse zeer selectieve 5-HT4-receptoragonisten opent perspectieven op volgende generatie gastro-intestinale (GI) geneesmiddelen
• Twee Movetis-geneesmiddelen doorlopen zoals gepland het fase II klinisch onderzoek in gastro-intestinale (GI) aandoeningen